BR112019024608A2 - Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21) - Google Patents
Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21) Download PDFInfo
- Publication number
- BR112019024608A2 BR112019024608A2 BR112019024608-8A BR112019024608A BR112019024608A2 BR 112019024608 A2 BR112019024608 A2 BR 112019024608A2 BR 112019024608 A BR112019024608 A BR 112019024608A BR 112019024608 A2 BR112019024608 A2 BR 112019024608A2
- Authority
- BR
- Brazil
- Prior art keywords
- fgf21
- promoter
- nucleotide sequence
- liver
- aav8
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/25—Animals on a special diet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201700615 | 2017-05-24 | ||
| EP17172818 | 2017-05-24 | ||
| EP17172818.1 | 2017-05-24 | ||
| ES201700615 | 2017-05-24 | ||
| PCT/EP2018/063707 WO2018215613A1 (en) | 2017-05-24 | 2018-05-24 | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019024608A2 true BR112019024608A2 (pt) | 2020-06-23 |
Family
ID=62620819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019024608-8A BR112019024608A2 (pt) | 2017-05-24 | 2018-05-24 | Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21) |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200102361A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3630160A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7778469B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110913886A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018274655B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019024608A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019013982A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018215613A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102765034B1 (ko) | 2017-05-24 | 2025-02-11 | 유니버시타트 아우토노마 데 바르셀로나 | 섬유아세포 성장 인자 21 (fgf21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트 |
| BR112019024608A2 (pt) * | 2017-05-24 | 2020-06-23 | Universitat Autonoma De Barcelona | Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21) |
| GB201818816D0 (en) * | 2018-11-19 | 2019-01-02 | Synpromics Ltd | Regulatory nucleic acid sequences |
| IL283452B2 (en) * | 2018-11-26 | 2026-04-01 | Univ Barcelona Autonoma | FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY |
| ES2948620T3 (es) | 2019-07-10 | 2023-09-14 | Masonic Medical Res Laboratory | Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo |
| MX2022004353A (es) | 2019-10-17 | 2022-07-19 | Casete de transferencia de aav. | |
| CN115916985A (zh) * | 2020-05-26 | 2023-04-04 | 巴塞罗那自治大学 | 用于中枢神经系统障碍的成纤维细胞生长因子21(fgf21)基因疗法 |
| CN113956344A (zh) * | 2021-10-14 | 2022-01-21 | 江南大学 | 一种新型治疗肝癌的fgf类似物及其应用 |
| CN114010666B (zh) * | 2021-10-22 | 2024-05-07 | 上海交通大学 | 溶瘤病毒、parp抑制剂及pd-1抗体在制备抗肿瘤药物中的应用 |
| CN114316018A (zh) * | 2021-11-26 | 2022-04-12 | 江南大学 | 一种fgf21蛋白类似物及其应用 |
| CN118460618A (zh) * | 2022-04-19 | 2024-08-09 | 康霖生物科技(杭州)有限公司 | 一种用于遗传性凝血因子缺乏病治疗的核酸构建体 |
| EP4598590A4 (en) * | 2022-10-08 | 2026-05-27 | Lingyi Biotech Co Ltd | CONSTRUCTION TO IMPROVE GENE EXPRESSION |
| WO2025158406A1 (en) * | 2024-01-26 | 2025-07-31 | Source Bio, Inc. | Compositions for adipose tissue targeting and uses thereof |
| CN118389554A (zh) * | 2024-05-10 | 2024-07-26 | 三峡大学 | 一种提高fgf-21持续表达水平和稳定性的aav重组病毒及其应用 |
| WO2025240610A2 (en) * | 2024-05-14 | 2025-11-20 | Rejuvenate Bio Inc | Fgf21 gene therapy and methods therefor |
| WO2026028137A1 (en) * | 2024-07-31 | 2026-02-05 | Universitat Autònoma De Barcelona | Fibroblast growth factor 21 (fgf21) gene therapy |
| WO2026133103A1 (en) * | 2024-12-16 | 2026-06-25 | Universitat Autònoma De Barcelona | Aav vectors for delivery of nucleic acids encoding fgf21 and methods of treating lung diseases using the same |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| US6133027A (en) | 1996-08-07 | 2000-10-17 | City Of Hope | Inducible expression system |
| EP1007637B1 (en) | 1997-04-14 | 2004-06-30 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant aav product |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| CN1247788C (zh) | 1997-05-13 | 2006-03-29 | 北卡罗来纳-查佩尔山大学 | 基于慢病毒的基因转移载体 |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
| EP1135468B1 (en) | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| DE19909769A1 (de) | 1999-03-05 | 2000-09-07 | Bundesrepublik Deutschland Let | Von SIVagm abgeleitete lentivirale Vektoren, Verfahren zu ihrer Herstellung und ihre Verwendung zur Genübertragung in Säugerzellen |
| AU6814901A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
| AU2001292881A1 (en) * | 2000-09-20 | 2002-04-02 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| AU2003274397A1 (en) | 2002-06-05 | 2003-12-22 | University Of Florida | Production of pseudotyped recombinant aav virions |
| US8951966B2 (en) * | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
| WO2013033452A2 (en) * | 2011-08-31 | 2013-03-07 | Amgen Inc. | Method of treating or ameliorating type 1 diabetes using fgf21 |
| EP2692868A1 (en) * | 2012-08-02 | 2014-02-05 | Universitat Autònoma De Barcelona | Adeno-associated viral (AAV) vectors useful for transducing adipose tissue |
| US9290557B2 (en) * | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| EP3798228A1 (en) * | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| CN105916990B (zh) * | 2013-08-02 | 2020-02-04 | 巴塞罗那自治大学 | 用于转导脂肪组织的腺相关病毒载体 |
| CN109844124B (zh) * | 2016-05-20 | 2023-10-03 | 哈佛学院董事及会员团体 | 年龄相关疾病和病症的基因治疗方法 |
| BR112019024608A2 (pt) | 2017-05-24 | 2020-06-23 | Universitat Autonoma De Barcelona | Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21) |
| IL283452B2 (en) * | 2018-11-26 | 2026-04-01 | Univ Barcelona Autonoma | FIBROBLAST GROWTH FACTOR 21 (FGF21)-BASED GENE THERAPY |
-
2018
- 2018-05-24 BR BR112019024608-8A patent/BR112019024608A2/pt unknown
- 2018-05-24 US US16/615,854 patent/US20200102361A1/en not_active Abandoned
- 2018-05-24 EP EP18731359.8A patent/EP3630160A1/en active Pending
- 2018-05-24 MX MX2019013982A patent/MX2019013982A/es unknown
- 2018-05-24 AU AU2018274655A patent/AU2018274655B2/en active Active
- 2018-05-24 WO PCT/EP2018/063707 patent/WO2018215613A1/en not_active Ceased
- 2018-05-24 CN CN201880047871.5A patent/CN110913886A/zh active Pending
- 2018-05-24 JP JP2019565341A patent/JP7778469B2/ja active Active
-
2023
- 2023-05-30 JP JP2023089121A patent/JP7888501B2/ja active Active
-
2025
- 2025-04-29 AU AU2025203001A patent/AU2025203001A1/en active Pending
-
2026
- 2026-03-31 JP JP2026059364A patent/JP2026119083A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018215613A1 (en) | 2018-11-29 |
| JP7888501B2 (ja) | 2026-07-13 |
| AU2018274655B2 (en) | 2025-01-30 |
| JP2023109992A (ja) | 2023-08-08 |
| AU2025203001A1 (en) | 2025-05-22 |
| RU2019142845A3 (cg-RX-API-DMAC7.html) | 2021-09-20 |
| EP3630160A1 (en) | 2020-04-08 |
| AU2025203001A9 (en) | 2026-03-05 |
| JP2020530977A (ja) | 2020-11-05 |
| AU2018274655A1 (en) | 2019-12-19 |
| US20200102361A1 (en) | 2020-04-02 |
| RU2019142845A (ru) | 2021-06-24 |
| JP7778469B2 (ja) | 2025-12-02 |
| MX2019013982A (es) | 2020-07-22 |
| CN110913886A (zh) | 2020-03-24 |
| JP2026119083A (ja) | 2026-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7778469B2 (ja) | 線維芽細胞増殖因子21(fgf21)コーディング配列を含むウイルス発現コンストラクト | |
| Pozsgai et al. | Systemic AAV-mediated β-sarcoglycan delivery targeting cardiac and skeletal muscle ameliorates histological and functional deficits in LGMD2E mice | |
| Xie et al. | Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor | |
| Cao et al. | Molecular therapy of obesity and diabetes by a physiological autoregulatory approach | |
| EP3364996B1 (en) | Prostate-targeting adeno-associated virus serotype vectors | |
| Bates et al. | Adipose tissue: an emerging target for adeno-associated viral vectors | |
| US10286085B2 (en) | Compositions and methods for treatment of muscular dystrophy | |
| US9265843B2 (en) | Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor | |
| US9890394B2 (en) | Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders | |
| O'Neill et al. | Targeting adipose tissue via systemic gene therapy | |
| RU2765826C2 (ru) | Векторная система на основе аденоассоциированного вируса | |
| US20260139021A1 (en) | Viral expression construct comprising a fibroblast growth factor (fgf21) coding sequence | |
| CA3179874A1 (en) | Fibroblast growth factor 21 (fgf21) gene therapy for central nervous system disorders | |
| US20140199272A1 (en) | Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity | |
| BR112021002202A2 (pt) | mini-gde para o tratamento de doença de armazenamento de glicogênio iii | |
| Eriksson et al. | Optimized riboswitch-regulated AAV vector for VEGF-B gene therapy | |
| ES2948620T3 (es) | Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo | |
| JP7837963B2 (ja) | 糖尿病を処置するための修飾型インスリンおよびグルコキナーゼ核酸 | |
| CA3130196A1 (en) | Production of large-sized quasidystrophins using overlapping aav vectors | |
| BR122025000954A2 (pt) | Construto de expressão viral que compreende uma sequência de codificação do fator de crescimento de fibroblastos 21 (fgf21) | |
| Hashimoto et al. | Study on AAV-mediated gene therapy for diabetes in humanized liver mouse to predict efficacy in humans | |
| US20250288693A1 (en) | Insulin and glucokinase gene therapy compositions and its use for treating diabetes | |
| CA3063979A1 (en) | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence | |
| Vitale et al. | Helper-dependent adenoviral vector-mediated expression of an LDL receptor/transferrin chimeric protein in muscle safely reduces atherosclerosis in LDLR-deficient mice. | |
| Rajendiran et al. | Combination Gene Therapy with AAV-Based Vectors Ameliorates the Phenotype of Type 2 Diabetes in Diet-Induced Obese and db/db Mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025000954-7 PROTOCOLO 870250004079 EM 17/01/2025 15:08. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |